A carregar...
COT-22 TIMING OF SURGERY AND BEVACIZUMAB THERAPY FOR MALIGNANT GLIOMAS
BACKGROUND: The drug manufacturer recommends postponing initiation of bevacizumab for malignant gliomas at least 4 weeks later postoperatively. Malignant glioma patients with significant neurological deficits due to postoperative residual tumors are preferably needed earlier bevacizumab therapy that...
Na minha lista:
| Publicado no: | Neurooncol Adv |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7213452/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdz039.202 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|